SURVYR

KURA

Kura Oncology, Inc.
$10.72
+$0.82 (8.28%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-33%-19%-4%+11%+26%Oct 2025Oct 2026Apr 202652w high $13.9052w low $7.36
KURASPY
Wall St. Highest PT $76.00 (+609.0%) Wall St. Avg PT $31.85 (+197.1%)
$7$25$43$61$78POC $9Hi $76Avg $32
Underwater Drawdown %Max DD -39.0%Current -21.1%
0.0%-39.0%
Relative Strength vs SPY-16.8% vs SPYUnderperforming
+37%0%-37%
1W
+$0.84 (8.50%)
1M
+$0.11 (1.04%)
3M
+$1.79 (20.04%)
6M
+$1.97 (22.51%)
YTD
+$0.33 (3.18%)
1Y
+$0.21 (2.00%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
13 analysts · mean score 1.31
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$10.72
Average target$31.85
+$21.13 (+197.1%) upsideaverage target vs current price
CurrentAverageMedian
Low$15.00
Median$31.85
High$76.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Health check

Financial health
DistressGrey zoneSafe
Distress zone
Altman Z-score -2.9
Above 2.99 is the safe zone, below 1.81 the distress zone.
Quality
WeakAverageStrong
Weak
Piotroski F-score 2 of 9
See the tests
  • ✗Positive net income
  • ✗Positive operating cash flow
  • ✗Return on assets improved
  • ✓Cash flow above net income
  • ✗Long-term debt / assets fell
  • ✗Current ratio improved
  • ✗No share dilution
  • ✗Gross margin improved
  • ✓Asset turnover improved

Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.

Key stats & company

Market value$870.0M
P/E (next 12 months, estimated)-4.2
52-week range$7.36 – $13.90
Revenue growth (latest quarter vs a year ago)+36.5%
Dividend yieldNo dividend
Analyst consensusStrong Buy (13)
Average analyst price target$31.85 (+197%)

What they do

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score -1 (DCF counts double).
▼Piotroski F-score2/9
▼Altman Z-2.9 (distress)
▲Analyst target+197% (13 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.47 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $-2.35 vs trailing $-3.37. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
–
Operating margin
-411.9%
FCF margin
-152.1%
Net margin
-384.3%
Return on equity
-612.8%
Return on invested capital
–
Net debt / EBITDA
–
Current ratio
4.7×
Interest cover
-224.0×
Cash conversion (OCF/NI)
–
Piotroski F-score 2/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score -2.9 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$32
+197%
Analysts
13
Strong Buy
Range
$15–$76
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$67.5M$-278.7M$-70.7M
2024$53.9M$-174.0M$133.8M
2023$0$-152.6M$-125.0M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.

For information only · Important disclosures

Grades vs sector

No sector grades for KURA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

Next report: –
No EPS history available.

News & catalysts

More news
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
Zacks · Oct 27
Insider trades
Powl Brian T.
Chief Commercial Officer · 2026-09-29
Sell
$165.9K
Leoni Mollie
Chief Medical Officer · 2026-09-29
Sell
$309.6K
Ford Kathleen
Chief Operating Officer · 2026-09-29
Sell
$39.4K
Powl Brian T.
Chief Commercial Officer · 2026-09-28
Sell
$84.5K
Powl Brian T.
Chief Commercial Officer · 2026-09-28
Sell
$94.7K
Doyle Thomas James
SVP, Finance & Accounting · 2026-09-28
Sell
$48.4K
Leoni Mollie
Chief Medical Officer · 2026-09-28
Sell
$130.7K
Ford Kathleen
Chief Operating Officer · 2026-09-28
Sell
$72.5K
Bair Teresa Brophy
Chief Legal Officer · 2026-09-28
Sell
$88.6K
Burrows Francis
Chief Scientific Officer · 2026-09-24
Sell
$224.5K
Wilson Troy Edward
Director, President and CEO · 2026-08-24
Buy
$1.2M
Powl Brian T.
Chief Commercial Officer · 2026-08-21
Sell
$51.7K

Stats refreshed 2026-10-22 12:46:17 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026